News | February 20, 2025
Innocan Pharma granted first patent in India for its Liposomal CBD Injection
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Plans underway to expand screening capacity by 50% for greater accessibility
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Subscribe To Our Newsletter & Stay Updated
